Britain backs GSK's gene therapy for 'bubble boy' syndrome

(Reuters) - GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news